{ }
001122334455554433221100
001122334455554433221100

TME Pharma advances glioblastoma treatment with promising NOX-A12 trial results

TME Pharma N.V. reported significant advancements in its clinical and regulatory efforts for NOX-A12, a treatment for glioblastoma, achieving a median overall survival of 19.9 months in a recent trial. The FDA granted Fast Track designation and cleared an IND application for a Phase 2 study, paving the way for accelerated development. The company also raised €5 million in funding, enhancing its financial position as it prepares for further clinical trials.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Machinary - Dashboard

Client connection lost

Please check your connection. We try to reconnect...

Server connection lost

If our server is updating to a new version, please wait a moment before the service is available again.

Connection refused

All connection attempts have been rejected. This is most likely due to network problems or server problems.